ARWR · Arrowhead Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $12.20B |
| P/E | — |
| Float | 135.6M |
| Beta | 1.30 |
| Volatility | 32.5% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 66 |
| Price | 85.44 |
| Change | −1.04% |
| Prev Close | 86.34 |
| Open | 85.87 |
| Day Low | 84.20 |
| Day High | 86.96 |
| Avg Vol | 1 |
| Avg $ Vol | $100.7M |
| 52W High | 95.49 |
| 52W Low | 27.10 |
| 52W Pos | 85.3% |
| From High | −10.52% |
| From Low | +215.28% |
| Max DD 1Y | −24.64% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.75% |
| SMA 50 | +1.70% |
| SMA 200 | +20.11% |
| RSI (14) | 51.5 |
| Vol 30D | 31.9% |
| Vol 90D | 54.2% |
| 1Y Range | 27–95 |
| Daily bars | 887 |
| Perf Week | +1.68% |
| Perf Month | +0.59% |
| Perf Quarter | +18.13% |
| Perf Half Y | +44.33% |
| Perf Year | +208.36% |
| Perf YTD | +26.04% |
| Prev Day | −1.04% |
| Clavix | C+ |
| Debt / Eq | 1.34 |
| Curr Ratio | 4.86 |
| Int Cover | -4.1× |
| FCF Margin | 16.3% |
| Rev Growth | +171.0% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 23 / 35 |
Clavix risk grade
regraded every trading dayARWR grades C+, 66 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (49, fragile). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 23 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ARWR | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.30 | 0.50 |
| Volatilityannualized | 32.5% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −24.6% | — |
| Typical daily movemedian absolute daily change | 2.07% | — |
| Days beyond ±3%of the last 252 sessions | 8233% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ARWR | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.30 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ARWR | |
|---|---|
| 1 week | +1.7% |
| 1 month | +0.6% |
| Year to date | +26.0% |
| 1 year | +208.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ARWR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 23 Jul |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 1 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ARWR | |
|---|---|
| Revenue growthyear over year | +171.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | ARWR | Sector spread | Median |
|---|---|---|---|
| Beta | 1.30 | 0.50 | |
| Volatility | 32.5% | 13.2% | |
| Debt / equity | 1.34 | 0.24 | |
| Current ratio | 4.86 | 3.73 | |
| FCF margin | 16.3% | 29.1% | |
| Interest coverage | -4.1× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openArrowhead Pharmaceuticals reported detailed Phase 3 results from the SHASTA-3 and SHASTA-4 studies of plozasiran in 757 adults with severe hypertriglyceridemia (very high triglyceride levels in the blood). Four quarterly 25-mg doses cut triglyceride levels by 79% and 81% at 12 months, versus about 27% for placebo, and a pooled analysis showed a 78% lower rate of pancreatitis (dangerous inflammation of the pancreas) events. The article raises the question of whether the absolute pancreatitis benefit is large enough to justify a broader drug label.
Arrowhead Pharmaceuticals presented Phase 3 clinical trial results (called SHASTA-3 and SHASTA-4) for its drug plozasiran at the ESC Congress 2026, showing it lowered triglyceride levels (a type of fat in the blood) and reduced episodes of acute pancreatitis (sudden inflammation of the pancreas) in patients with severely elevated triglycerides.
Arrowhead Pharmaceuticals said its drug plozasiran, in two late-stage trials, substantially lowered blood fat (triglyceride) levels and reduced sudden pancreas inflammation episodes in adults with severely elevated triglycerides compared to a placebo. The 12-month data was presented at a European cardiology conference and accepted for publication in a major medical journal.
Arrowhead Pharmaceuticals said its drug plozasiran, in two late-stage (Phase 3) trials called SHASTA-3 and SHASTA-4, substantially lowered triglyceride levels and reduced sudden pancreas inflammation (acute pancreatitis) events compared to a placebo in adults with very high blood fat levels (severe hypertriglyceridemia), based on 12-month results.
Royal Bank of Canada reaffirmed an "outperform" rating on Arrowhead Pharmaceuticals and set a $100 share price target in a research note issued Monday. The article contains no other information about the company.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MDGL | Madrigal Pharmaceuticals Inc | B | $12.50B | — | -1.10 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $12.51B | 30.24 | 0.96 | Compare |
| KRYS | Krystal Biotech Inc | B | $10.60B | 43.91 | 0.55 | Compare |
| EXEL | Exelixis Inc | B+ | $14.62B | 16.99 | 0.48 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $14.63B | — | 0.96 | Compare |
| CYTK | Cytokinetics Inc | B | $10.11B | — | 0.39 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $9.65B | — | 0.38 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $9.43B | 113.73 | 1.18 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.